ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021

November 10, 2021 GMT

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, Founder and Chief Executive Officer, will present and participate in one-on-one investor meetings at several upcoming investor conferences in November. Details of these presentations and associated conferences can be found below:

Jefferies London Healthcare Conference (November 16-18, 2021)  
Format:            Fireside Chat  
Time and Date: 5:00-5:35 PM GMT (12:00-12:35 p.m. EST) on Tuesday, November 16, 2021
   
Evercore ISI 4th Annual HealthCONx (November 30 – December 2, 2021)  
Format: Fireside Chat
Time and Date: 2:40-3:00 PM EST on Tuesday, November 30, 2021
   
Piper Sandler 33rd Healthcare Conference (November 30 – December 2, 2021)  
Format: Fireside Chat
Time and Date: Available on-demand beginning at 10:00 AM EST on November 22, 2021
   
ADVERTISEMENT

A replay link of each presentation will be available for 30 days and can be accessed by visiting the “ Presentations ” section of the Vera Therapeutics website at www.veratx.com.

About Vera Therapeutics
Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus. For more information, please visit www.veratx.com.

ADVERTISEMENT

Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will”, “anticipates,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Vera’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Vera’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Greig Communications, Inc.
Kathy Vincent
(310) 403-8951
kathy@greigcommunications.com